January 12, 2018
Sonoran Biosciences welcomes three new Clinical Advisors
Sonoran Biosciences, Inc., a preclinical-stage pharmaceutical company developing a novel antibacterial gel for the treatment and prevention of serious biofilm infections, today announced it is welcoming Antonia Chen, MD, MBA, Mark Spangehl, MD, and Bryan Springer, MD as Clinical Advisors. The Clinical Advisors will provide strategic guidance to the company’s product development efforts. All three of the Clinical Advisors are nationally-recognized orthopaedic surgeons with a special interest in infection prevention and treatment.
Dr. Chen is an orthopaedic surgeon and is an Associate Professor at the Sidney Kimmel School of Medicine at Thomas Jefferson University. She is the current President of the Musculoskeletal Infection Society (MSIS) who recently accepted the position of head of Arthroplasty Research at Brigham and Women’s Hospital in Boston, where she will focus on infection research. She has received multiple awards for clinical and basic science research focused on the diagnosis and management of prosthetic joint infection, and she completed an Adult Reconstruction fellowship at Rothman Institute. She has authored over 120 articles in peer-reviewed journals, several authoritative book chapters, and she has held administrative positions in a number of national and international societies.
Dr. Spangehl is an orthopaedic surgeon and educator. He is an Associate Professor at Mayo Clinic in Arizona and founded both the Orthopaedic Surgery Residency and Adult Reconstructive Surgery Fellowship at Mayo Clinic’s campus in Phoenix, Arizona. He has over 15 years experience in clinical practice and research focused on total hip and knee replacement, including management of complications including postoperative pain and infection. He has published numerous peer-reviewed articles focused on diagnosis and management of prosthetic joint infection and postoperative pain management. Dr. Spangehl was contributor to the MSIS criteria for the diagnosis of prosthetic joint infection and has served in leadership roles for national orthopaedic societies in their activities related to prosthetic joint infection.
Dr. Springer is an orthopaedic surgeon, Associate Professor in the Department of Orthopedic Surgery at Carolinas Medical Center, Fellowship Director at OrthoCarolina, and a past President of MSIS. He has received national recognition from the Knee Society and AAHKS, and in 2014 was named one of the Top 22 North American Knee Surgeons by Orthopedics This Week. He is currently a member of both The Hip Society and The Knee Society and serves as Education Chair for AAHKS. He has authored over 85 peer-reviewed articles, over 25 book chapters, and three textbooks focused primarily on complex total hip and knee replacement and infection.
About Sonoran Biosciences, Inc.
Sonoran Biosciences is a preclinical-stage pharmaceutical company developing a novel antibacterial gel for the treatment and prevention of serious biofilm infections, especially those that occur after surgery. The company’s lead product SBG002 is an injectable sustained-release gel containing tobramycin and vancomycin designed for direct application in surgical sites. SBG002 has the potential to become a first-in-class product for treatment and prevention of a wide variety of serious infections, and is being developed toward a lead indication in one-stage treatment of periprosthetic joint infection (PJI), the most common and costly reason for failed arthroplasty.